Press Releases

Oct 7, 2022

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

Aug 15, 2022

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Jul 28, 2022

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

Jul 21, 2022

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

Jul 19, 2022

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Jul 11, 2022

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

Jul 5, 2022

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

Jun 15, 2022

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

Jun 13, 2022

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

Jun 8, 2022

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value